Literature DB >> 6357060

Immunity to influenza in man.

R B Couch, J A Kasel.   

Abstract

The observations summarized in this review indicate immunity to infection with type A influenza viruses is subtype specific since little or none is conveyed to subtypes possessing immunologically distinct HA and NA proteins. However, within a subtype, a prior antigenic experience with one variant may prevent or modify illness to another. The resulting degree of subtype immunity depends on the extent of relatedness between variants. Observations with H3N2 viruses indicate that homotypic resistance to subsequent infection and illness with the same virus is potent and of relatively long duration. The long lasting durability of such immunity was indicated by the epidemiologic pattern following the reappearance of H1N1 virus. Knowledge of the duration and specificity of immunity aids considerably in assessing mechanisms that account for host resistance to influenza. Recovery from influenza virus infection must involve a variety of humoral and cell-mediated immune mechanisms, and conclusions regarding the relative importance of each one are not possible at present. To prevent infection, involved immune mechanism(s) must account for: (a) subtype specificity, (b) reduced cross-reactivity of immunity for succeeding antigenic variants, (c) a long duration of immunity, and (d) immunity at the mucosal surface. Only antibody directed toward the HA molecule presently satisfies these properties and thus should be considered the major mediator of resistance to infection. Study of naturally occurring infection is needed for determining the duration and specificity of secretory IgA in nasal and lower respiratory secretions so as to establish its relative importance as a mediator of immunity. However, the described duration, specificity, and consistent relationship to immunity suggest that IgG antibody in respiratory secretions, derived entirely or partly from serum, is the most likely mediator of resistance to natural influenza.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357060     DOI: 10.1146/annurev.mi.37.100183.002525

Source DB:  PubMed          Journal:  Annu Rev Microbiol        ISSN: 0066-4227            Impact factor:   15.500


  129 in total

1.  Depletion of human NK and CD8 cells prior to in vitro H1N1 flu vaccine stimulation increases the number of gamma interferon-secreting cells compared to the initial undepleted population in an ELISPOT assay.

Authors:  Christophe Dercamp; Violette Sanchez; Julie Barrier; Emanuelle Trannoy; Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 2.  Current research on respiratory viral infections: Third International Symposium.

Authors:  A C Schmidt; R B Couch; G J Galasso; F G Hayden; J Mills; B R Murphy; R M Chanock
Journal:  Antiviral Res       Date:  2001-06       Impact factor: 5.970

3.  High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.

Authors:  E Kretzschmar; L Buonocore; M J Schnell; J K Rose
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses.

Authors:  Yolanda D Mahnke; Areej Saqr; Staci Hazenfeld; Rebecca C Brady; Mario Roederer; Ramu A Subbramanian
Journal:  Vaccine       Date:  2011-09-20       Impact factor: 3.641

5.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

6.  Positive Selection in CD8+ T-Cell Epitopes of Influenza Virus Nucleoprotein Revealed by a Comparative Analysis of Human and Swine Viral Lineages.

Authors:  Heather M Machkovech; Trevor Bedford; Marc A Suchard; Jesse D Bloom
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

Review 7.  Protective B cell responses to flu--no fluke!

Authors:  Elizabeth E Waffarn; Nicole Baumgarth
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

8.  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

Authors:  Jack T Stapleton; Nancy Wagner; Rebecca Tuetken; Abbie R Bellamy; Heather Hill; Sonnie Kim; Patricia L Winokur
Journal:  Vaccine       Date:  2020-04-12       Impact factor: 3.641

Review 9.  Pathology of human influenza revisited.

Authors:  Thijs Kuiken; Jeffery K Taubenberger
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

10.  Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus.

Authors:  Chang-Won Lee; Dennis A Senne; David L Suarez
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.